VIBATIV is the only once-daily in vitro bactericidal antibiotic with a dual mechanism of action indicated for infections due to S. aureus, including MRSA and MSSA. VIBATIV is indicated for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates.
Astellas Pharma created a breakthrough product in the area of treatment for MRSA and cSSSI. With a unique dual mechanism of action, Vibativ could more efficaciously fight severe infections caused by methicillin-resistent staphylococci in adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).
Astellas wanted this campaign to be aggressive and arresting. The focus was to be around the dual MOA.
This is a second concept that the client brought into focus group testing, and it scored very high. The arresting visual clearly communicated 2 apex predators representing the duo MOA ready to kill MRSA.